RTO.L

Rentokil Initial Plc
Rentokil Initial PLC - Appointment of Non-Executive Director
25th September 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 5139F
Rentokil Initial PLC
25 September 2024
 

25 September 2024

 

 Appointment of Non-Executive Director

 

Rentokil Initial plc (FTSE: RTO, "the Company") today announces the appointment of Brian Baldwin to its Board as a Non-Executive Director with effect from 1 October 2024. He will also become a member of the Nomination Committee and Remuneration Committee from this date.

 

Mr. Baldwin is the Head of Research of Trian Fund Management, L.P. ("Trian"), an investment management firm. Mr Baldwin has been a Trian Partner since 2013 and a member of Trian's Investment Team since 2007. He has played leadership roles in many of Trian's investments.

 

Mr. Baldwin has been a non-executive director of Janus Henderson Group plc since 2022 and currently serves on the Board's Nominating and Corporate Governance Committee and the Risk Committee. From 2018 to 2020, he served as a director and member of the Compensation and Governance Committees of nVent Electric plc (formerly the electrical business of Pentair plc before becoming a standalone public company).

 

Prior to joining Trian, Mr. Baldwin was an analyst at Merrill Lynch Global Private Equity from 2005 to 2007. Mr. Baldwin received a B.S. degree, summa cum laude, from The Wharton School at the University of Pennsylvania.

 

Richard Solomons, Chairman of Rentokil Initial, said:

 

"We are delighted to welcome Brian to the Board of Rentokil Initial and we look forward to working with him to deliver long-term sustainable value for our shareholders and, in particular, executing our plans to integrate the Terminix business and to increase organic growth in our North America operations. We continue to work towards the substantial structural growth opportunities for our pest control business, enhanced by the benefits of the Terminix transaction."

 

Brian Baldwin said:

 

"I welcome the opportunity to join the Board of Rentokil Initial. Trian believes Rentokil has significant potential and runway for growth that can be achieved by leveraging its strong brands and market leading positions, particularly in the US. I look forward to working with management and the Board to identify options to help drive long-term value that will benefit all stakeholders."

 

Trian has confirmed to the Company that it manages investment vehicles owning approximately 57.1 million shares of Rentokil Initial (approximately 2.26% of shares outstanding).

 

There are no further details to be disclosed relating to Brian Baldwin under Section 6.4.8 of the UK Listing Rules.

 

 

 

For further information please contact:

 

Rentokil Initial plc

Investors

Peter Russell

07795 166506

Media

Malcolm Padley

07788 978 199

Company Secretary

Rachel Canham

01293 858 000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAZZGZLLDDGDZM]]>
TwitterFacebookLinkedIn